Skip to main content

What the FDA labels say about taking them together

Acebutolol and tasimelteon

Tasimelteon's FDA label of August 4, 2026 names acebutolol in its drug interactions section; the acebutolol label PlainMeds reads does not name tasimelteon. The tasimelteon label: “Antagonists Beta-adrenergic receptor antagonists have been shown to reduce the production of melatonin via specific inhibition of beta-1 adrenergic receptors.”

Check it at the source: the acebutolol FDA label on DailyMed (effective December 11, 2024, Amneal Pharmaceuticals of New York LLC); the tasimelteon FDA label on DailyMed (effective August 4, 2026, Vanda Pharmaceuticals Inc.).

What does the acebutolol label say about tasimelteon?

Acebutolol's label (effective December 11, 2024) does not name tasimelteon in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Acebutolol Hydrochloride), Amneal Pharmaceuticals of New York LLC, effective December 11, 2024 (SPL set fe2cd5c0-ee16-4bcb-ad92-3755881dbe79), via openFDA; the full label on DailyMed

What does the tasimelteon label say about acebutolol?

Tasimelteon label, drug interactions

Antagonists (e.g., acebutolol, metoprolol) Beta-adrenergic receptor antagonists have been shown to reduce the production of melatonin via specific inhibition of beta-1 adrenergic receptors.

Source: FDA drug label (Hetlioz), Vanda Pharmaceuticals Inc., effective August 4, 2026 (SPL set ca4a9b63-708e-49e9-8f9b-010625443b90), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

6Acebutolol generic labelers
3Tasimelteon generic labelers
AcebutololTasimelteon
Labeled forHigh blood pressuren/a
Boxed warningNoNo
Pharmacy cost (NADAC)$0.615 per capsule 200 mg capsule$228.25 per capsule 20 mg capsule
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?